1292317-56-6 Usage
Description
D0128, also known as D-glucuronic acid, is a naturally occurring sugar acid derived from glucose with the molecular formula C10H16N2O8. It plays a vital role in the structure and function of connective tissues as a key component of the extracellular matrix. Furthermore, D0128 is involved in the detoxification and elimination of drugs and other toxic substances in the body, making it a subject of interest for its potential therapeutic applications in treating various diseases, including cancer and inflammation, as well as promoting wound healing and tissue repair.
Uses
Used in Pharmaceutical Industry:
D0128 is used as a therapeutic agent for its potential applications in the treatment of various diseases such as cancer and inflammation. Its involvement in detoxification and elimination processes makes it a promising candidate for managing and treating these conditions.
Used in Tissue Repair and Wound Healing:
D0128 is used as a promoter of wound healing and tissue repair due to its role in maintaining the structure and function of connective tissues. This makes it a valuable component in the development of treatments for injuries and other conditions requiring tissue regeneration.
Used in Detoxification Processes:
D0128 is utilized in detoxification processes for its role in the elimination of drugs and other toxic substances from the body. This application is particularly relevant in the development of treatments aimed at reducing the harmful effects of toxins and enhancing the body's natural detoxification mechanisms.
Check Digit Verification of cas no
The CAS Registry Mumber 1292317-56-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,9,2,3,1 and 7 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1292317-56:
(9*1)+(8*2)+(7*9)+(6*2)+(5*3)+(4*1)+(3*7)+(2*5)+(1*6)=156
156 % 10 = 6
So 1292317-56-6 is a valid CAS Registry Number.
1292317-56-6Relevant articles and documents
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain
Bagal, Sharan K.,Andrews, Mark,Bechle, Bruce M.,Bian, Jianwei,Bilsland, James,Blakemore, David C.,Braganza, John F.,Bungay, Peter J.,Corbett, Matthew S.,Cronin, Ciaran N.,Cui, Jingrong Jean,Dias, Rebecca,Flanagan, Neil J.,Greasley, Samantha E.,Grimley, Rachel,James, Kim,Johnson, Eric,Kitching, Linda,Kraus, Michelle L.,McAlpine, Indrawan,Nagata, Asako,Ninkovic, Sacha,Omoto, Kiyoyuki,Scales, Stephanie,Skerratt, Sarah E.,Sun, Jianmin,Tran-Dubé, Michelle,Waldron, Gareth J.,Wang, Fen,Warmus, Joseph S.
, p. 6779 - 6800 (2018)
Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, and TrkC). Moreover, in
TANK-BINDING KINASE INHIBITOR COMPOUNDS
-
Page/Page column 60, (2015/12/24)
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON
-
Page/Page column 96, (2011/05/05)
The invention relates to certain aminopyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).
